Literature DB >> 12095150

An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.

Guillermo J Ruiz-Argüelles1, Briceida López-Martínez, Eduardo Lobato-Mendizábal, Guillermo J Ruiz-Delgado.   

Abstract

BACKGROUND: The chronic myeloproliferative diseases (CMPDs) include chronic myelogenous leukemia (CML), primary (essential) thrombocythemia (PT), agnogenic myeloid metaplasia (AMM), and polycythemia vera (PV). Certain hematological malignancies have a different prevalence in our country than in countries with Caucasian populations. Data indicate that the prevalence of CML in our country is similar to that found in Caucasians; however, the prevalence of the other CMPDs has not been studied.
METHODS: In a total of 8069 individuals studied between June 1983 and March 2001 in the Centro de Hematologia y Medicina Interna de Puebla, we assessed the prevalence of CML, PT, AMM, and PV. Some of the clinical features of these individuals were also assessed. RESULTS AND
CONCLUSIONS: Forty-nine patients with CML, 14 with PT, 7 with AMM, and 3 with PV were identified. The clinical presentations of these CMPDs were not different from those described in Caucasians.
CONCLUSIONS: We found that CML was more than 3 times more frequent than PT, that both PV and AMM were exceptional, and that PT, AMM, and PV were significantly less frequent in Mexican than in Caucasian populations (P < .01).

Entities:  

Mesh:

Year:  2002        PMID: 12095150     DOI: 10.1007/bf02982113

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Gene frequencies and admixture estimates in four Mexican urban centers.

Authors:  R Lisker; E Ramirez; R P Briceño; J Granados; V Babinsky
Journal:  Hum Biol       Date:  1990-12       Impact factor: 0.553

2.  Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.

Authors:  G J Ruiz-Argüelles; G J Ruiz-Delgado; G Ruiz-Reyes; S G Chernoff
Journal:  Mayo Clin Proc       Date:  1998-11       Impact factor: 7.616

3.  Promyelocytic leukemia in Mexican Mestizos.

Authors:  G J Ruiz-Argüelles
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

Review 4.  ABC of clinical haematology. Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis.

Authors:  M Messinezy; T C Pearson
Journal:  BMJ       Date:  1997-02-22

Review 5.  Treatment of essential thrombocythemia with anagrelide.

Authors:  M N Silverstein; A Tefferi
Journal:  Semin Hematol       Date:  1999-01       Impact factor: 3.851

6.  [Chronic lymphocytic leukemia 1. Thirty five years experience at the Instituto Nacional de la Nutrición Salvador Zubirán. (Mexico) [].

Authors:  D D Alemán-Hoey; G J Ruiz-Argüelles; L Verduzco-Rodríguez; B López-Ariza; J R Labardini
Journal:  Rev Invest Clin       Date:  1982 Apr-Jun       Impact factor: 1.451

7.  Molecular monitoring of the treatment of patients with BCR/ABL (+) chronic myelogenous leukemia.

Authors:  G J Ruiz-Argüelles; B López-Martínez; J M Ramírez-Cabrera; V Reyes-Núñez; H M Rodríguez-Cedeño; J Garcés-Eisele
Journal:  Rev Invest Clin       Date:  2001 May-Jun       Impact factor: 1.451

8.  Assessment of residual disease in acute leukemia by means of polymerase chain reaction.

Authors:  G J Ruiz-Argüelles; J Garcés-Eisele; V Reyes-Núñez; B Pérez-Romano; A Ruiz-Argüelles; F J Ramírez-Cisneros; B López-Martínez; J D López-Tapia; L Rivadeneyra-Espinoza
Journal:  Rev Invest Clin       Date:  2000 Mar-Apr       Impact factor: 1.451

9.  Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study.

Authors:  G J Ruiz-Argüelles; E Lobato-Mendizábal; J F San-Miguel; M González; M D Caballero; A Ruiz-Argüelles; A Orfao; D Gómez-Almaguer; B Vidriales; G Ruiz-Reyes
Journal:  Br J Haematol       Date:  1992-12       Impact factor: 6.998

10.  Primary thrombocythaemia: a composite approach to diagnosis.

Authors:  M Messinezy; N Westwood; B Sawyer; R Grace; L J Holland; A S Lawrie; T C Pearson
Journal:  Clin Lab Haematol       Date:  1994-06
View more
  1 in total

1.  Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations.

Authors:  J S Velarde-Félix; J Sanchez-Zazueta; F P Gonzalez-Ibarra; J A González-Valdez; B Salcido-Gómez; E Gallardo-Angulo; J Murillo-Llanes
Journal:  West Indian Med J       Date:  2014-06-10       Impact factor: 0.171

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.